ACTIfit, has recently been awarded US FDA Breakthrough Designation. It is a proprietary biodegradable, biocompatible scaffold developed to address irreparable meniscus tears, one of the largest unmet needs in Orthopedic/ Sports Medicine. The ACTIfit scaffold supports the regeneration of new tissue in the meniscus, a fibrocartilage cushion (shock absorber) in the knee critical to cartilage protection, and future joint health.
CartiONE, is a single surgery, one-hour, Autologous Chondrocyte Implantation (ACI) cell service designed to harvest and combine a patient’s fresh cartilage cells (chondrocytes) and their bone marrow-derived cells to enable the growth of new (Hyaline-like) cartilage.
We are committed to identifying and developing innovative healthcare products that offer surgeons and their patients solutions for debilitating acute and chronic injuries. We are dedicated to helping people achieve pain relief, regain their mobility and quality of life.
ACTIfit has been developed over the past two decades, refined and focused for clinical use in over 4,000 patients. It possesses unique properties that make it an effective, biodegradable scaffold to facilitate regeneration of new tissue. The ACTIfit meniscal scaffold received its CE Mark renewal on July 17, 2019, was approved by the KFDA in Korea on February 19, 2020 and received US FDA Breakthrough Designation on April 1, 2020.
The CartiONE concept harnesses the healing properties of the patient’s tissues and cells. The technology combines cartilage cells (chondrocytes) with concentrated bone marrow cells to generate new cartilage. A main feature of this unique technology is the rapid isolation of fresh chondrocytes from the cartilage biopsy within 45 mins—ideal for a single-stage procedure.